Replimune Plunges 56% YTD After Second FDA Rejection: Leverage Risks and Biotech Sector Contagion

Event Summary

As reported by FierceBiotech and BioPharma Dive, the U.S. Food and Drug Administration issued a second Complete Response Letter (CRL) on April 10, 2026, rejecting Replimune Group's (NASDAQ: REPLI) RP1 (vusolimogene oderparepvec) for unresectable advanced cutaneous melanoma. The FDA's Office of Therapeutic Products unanimously concluded that data from the Phase 1/2 Ignyte trial were "insufficient to conclude substantial evidence of effectiveness," citing inadequate trial design and patient population heterogeneity. This marks the second rejection in nine months, following an initial CRL in July 2025.

Replimune's stock fell approximately 20% on the day to close at $4.76 from $5.91, extending a year-to-date decline of roughly 51%, according to Morningstar. Critically, a February 2026 SEC filing warned that a second rejection could lead the company to determine RP1 development is "no longer viable" — with Phase 3 trial completion not expected until January 2029.

Leverage Impact Analysis

For CFD traders using leverage on REPLI, this event illustrates the acute binary risk embedded in clinical-stage biotech positions. A trader holding a 50x long REPLI CFD opened at $5.91 would have seen equity wiped out well before the close — a 2% adverse move triggers a margin call at 50x, meaning the ~20% single-day decline represented roughly 10x the initial margin on that position.

On the short side, traders who anticipated the rejection faced a more complex picture: anyone entering a high-leverage short *after* October 2025's resubmission rally likely captured a significant portion of the 51% YTD decline. However, given the stock is now trading at distressed levels near $4.76, further high-leverage short entries carry asymmetric risk — a pipeline announcement or buyout rumor could trigger violent short squeezes.

Position sizing is paramount here. Given REPLI's thin float and regulatory binary nature, even moderate leverage (10x–20x) on single-name biotech CFDs carries liquidation risk on intraday volatility spikes. Traders should monitor margin requirements and consider volatility-adjusted sizing rather than fixed notional exposure.

Cross-Market Impact

The Replimune rejection amplifies sector-wide regulatory uncertainty. Nearly half of investors surveyed by RBC Capital Markets already cited the "uncertain regulatory climate" as biotech's biggest issue. The State Street SPDR S&P Biotech ETF (XBI) and iShares Nasdaq Biotechnology ETF (IBB) face downside pressure as clinical-stage oncology companies with single-arm trial designs reprice regulatory risk premiums.

The broader NASDAQ 100 Index and S&P 500 Index see limited direct impact given Replimune's small market cap, but persistent biotech sector weakness can contribute to risk-off rotation in growth equities. Bristol Myers Squibb (BMY), as Opdivo's manufacturer and RP1's combination partner, faces minor indirect exposure, though its diversified portfolio limits material damage. Our 2026 Stocks Market Outlook provides broader sector context for navigating this regulatory environment.

Trading Considerations

With REPLI now down ~51% YTD and pipeline viability in question, the stock is in distressed territory. Key levels to watch: a breakdown below the $4.76 close risks further downside toward book value; any positive pipeline catalyst or M&A speculation could create sharp mean-reversion spikes. For sector ETF traders, XBI's reaction over the next 48 hours will signal whether contagion is broadening. The departure of FDA biologics head Vinay Prasad by end of April 2026 adds a wildcard — leadership transitions historically introduce short-term approval-pathway uncertainty across clinical-stage names. Check open interest and funding dynamics on CoinUnited.io for real-time confirmation signals before entering leveraged biotech positions.

Trade Avidity Biosciences, Inc. on CoinUnited.io

Trade RNAM with up to 1000xx leverage → | Create Free Account